- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Emerging strategies to overcome resistance to third-generation EGFR inhibitors ; volume:15 ; number:1 ; day:15 ; month:7 ; year:2022 ; pages:1-44 ; date:12.2022
Journal of hematology & oncology ; 15, Heft 1 (15.7.2022), 1-44, 12.2022
- Creator
-
Shi, Kunyu
Wang, Guan
Pei, Junping
Zhang, Jifa
Wang, Jiaxing
Ouyang, Liang
Wang, Yuxi
Li, Weimin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-022-01311-6
- URN
-
urn:nbn:de:101:1-2022120213250722500933
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shi, Kunyu
- Wang, Guan
- Pei, Junping
- Zhang, Jifa
- Wang, Jiaxing
- Ouyang, Liang
- Wang, Yuxi
- Li, Weimin
- SpringerLink (Online service)
Other Objects (12)
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology